

December 22, 2020

To whom it may concern

Company Name: Name of Representative: H.U. Group Holdings, Inc. Shigekazu Takeuchi

President & CEO

Code Number:

4544, 1st Section of Tokyo Stock Exchange

Application to the U.S. FDA for EUA Approval of High-sensitive Antigen Test for SARS-CoV-2

Fujirebio Diagnostics Inc. (Pennsylvania, USA; Monte Wiltse, CEO), a subsidiary company of Fujirebio Holdings, Inc., a consolidated subsidiary company of H.U. Group Holdings, Inc., has announced today that it has applied to the U.S. Food and Drug Administration for Emergency Use Authorization (EUA) approval of a high-sensitive antigen test for SARS-CoV-2.

Inquiries

Media:

Public Relations Department e-mail: pr@hugp.com

Investors/Analysts:

IR/SR Department e-mail: ir@hugp.com